Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT.W


Primary Symbol: V.TLT Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Theralase advances cancer research after private placement

Jonathon Brown 1 day ago

Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement

Accesswire 1 day ago

This company’s Photo Dynamic Therapy is transforming cancer treatment

Jocelyn Aspa April 9, 2024

Theralase patents new cancer vaccine in Canada

Trevor Abes  April 5, 2024

Theralase(R) Granted Canadian Cancer Vaccine Patent

Accesswire April 5, 2024

Theralase(R) Release's 4Q2023 Interim Financial Statements

Accesswire March 27, 2024

Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association

Accesswire March 26, 2024

Theralase donates laser therapy tech to help research Parkinson’s treatment

Jonathon Brown February 12, 2024

Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease

Accesswire February 12, 2024

Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

Accesswire February 8, 2024

Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement

Accesswire February 5, 2024

Theralase provides encouraging bladder cancer study results

Jocelyn Aspa January 15, 2024

Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study

Accesswire January 15, 2024

Theralase Release's 3Q2023 Interim Financial Statements

Accesswire November 29, 2023

Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement

Accesswire November 29, 2023

Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing

Accesswire November 17, 2023

Theralase(R) Announces Brokered LIFE Financing

Accesswire October 23, 2023

Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study

Accesswire October 23, 2023

Theralase(R) Provides Update on Bladder Cancer Clinical Study

Accesswire October 16, 2023

Theralase(R) Files US Patent for Enhanced Immunotherapy

Accesswire October 5, 2023